{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T11:54:19Z","timestamp":1768132459840,"version":"3.49.0"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s00277-021-04699-2","type":"journal-article","created":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T20:57:51Z","timestamp":1634590671000},"page":"1141-1144","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The first report of complete remission following treatment with venetoclax plus prednisone in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia"],"prefix":"10.1007","volume":"101","author":[{"given":"Yi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie-Jing","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yao-Jia","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Juan","family":"Hang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Hu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,18]]},"reference":[{"issue":"5","key":"4699_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1093\/annonc\/mdw025","volume":"27","author":"DBR Hoelzer","year":"2016","unstructured":"Hoelzer DBR, Dombret H (2016) Acute lymphoblastic leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 27(5):69\u201382","journal-title":"Ann Oncol"},{"issue":"2","key":"4699_CR2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1200\/jop.18.00271","volume":"15","author":"I Aldoss","year":"2019","unstructured":"Aldoss I, Forman SJ, Pullarkat V (2019) Acute lymphoblastic leukemia in the older adult. J Oncol Pract 15(2):67\u201375. https:\/\/doi.org\/10.1200\/jop.18.00271","journal-title":"J Oncol Pract"},{"issue":"4","key":"4699_CR3","first-page":"266","volume":"15","author":"M Yilmaz","year":"2017","unstructured":"Yilmaz M, Kantarjian H, Jabbour E (2017) Treatment of acute lymphoblastic leukemia in older adults: now and the future. Clin Adv Hematol Oncol 15(4):266\u2013274","journal-title":"Clin Adv Hematol Oncol"},{"issue":"6","key":"4699_CR4","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1038\/s41375-018-0315-6","volume":"33","author":"M Scherr","year":"2019","unstructured":"Scherr M, Kirchhoff H, Battmer K, Wohlan K, Lee C-W, Ricke-Hoch M, Erschow S, Law E, Kloos A, Heuser M, Ganser A, Hilfiker-Kleiner D, Heidenreich O, Eder M (2019) Optimized induction of mitochondrial apoptosis for chemotherapyfree treatment of BCR-ABL+ acute lymphoblastic leukemia. Leukemia 33(6):1313\u20131323","journal-title":"Leukemia"},{"issue":"7","key":"4699_CR5","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1158\/0008-5472.CAN-14-1849","volume":"75","author":"SE Alford","year":"2015","unstructured":"Alford SE, Kothari A, Loeff FC, Eichhorn JM, Sakurikar N, Goselink HM, Saylors RL, Jedema I, Falkenburg JH, Chambers TC (2015) BH3 inhibitor sensitivity and Bcl-2 dependence in primary acute lymphoblastic leukemia cells. Cancer Res 75(7):1366\u20131375. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-1849","journal-title":"Cancer Res"},{"issue":"17","key":"4699_CR6","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","volume":"383","author":"R Foa","year":"2020","unstructured":"Foa R, Bassan R, Vitale A, Elia L, Piciocchi A, Puzzolo MC, Canichella M, Viero P, Ferrara F, Lunghi M, Fabbiano F, Bonifacio M, Fracchiolla N, Di Bartolomeo P, Mancino A, De Propris MS, Vignetti M, Guarini A, Rambaldi A et al (2020) Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults. New England J Med 383(17):1613\u20131623. https:\/\/doi.org\/10.1056\/NEJMoa2016272","journal-title":"New England J Med"},{"key":"4699_CR7","doi-asserted-by":"crossref","unstructured":"Lacayo NJ PV, Stock W, et al. (2019) Safety and efficacy of venetoclax in combination with navitoclax in adult and pediatric relapsed\/refractory acute lymphoblastic leukemia and lymphoblastic lymphoma[abstract]. Blood 134 (1):Abstract285","DOI":"10.1182\/blood-2019-126977"},{"key":"4699_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.pharmthera.2018.10.009","volume":"195","author":"R Yamaguchi","year":"2018","unstructured":"Yamaguchi R, Lartigue L, Perkins G (2018) Targeting Mcl-1 and other Bcl-2 family member proteins in cancer therapy. Pharmacol Therapeutics 195:13\u201320","journal-title":"Pharmacol Therapeutics"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04699-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-021-04699-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04699-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T09:05:33Z","timestamp":1649408733000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-021-04699-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,18]]},"references-count":8,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["4699"],"URL":"https:\/\/doi.org\/10.1007\/s00277-021-04699-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,18]]},"assertion":[{"value":"14 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written consents were obtained from all patients following the Declaration of Helsinki, and the study was approved by the ethics committee of the First Affiliated Hospital of Zhejiang University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and informed consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}